Booth Bruce sold $44.0M of KYMR (indirect holdings)
Booth Bruce sold 398,765 indirectly-held shares of Kymera Therapeutics, Inc. (KYMR) at an average of $110.31 ($99.98–$118.60, $43.99M total) across 30 trades over 2026-06-23 to 2026-06-25 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the disclosed sale size ($43.99M) and the fact it was executed under a pre-arranged 10b5-1 plan, which typically dampens interpretive weight versus unscheduled selling.
Market read
Traders may briefly reassess sentiment around KYMR due to the magnitude of the director sale, but the 10b5-1 framing limits fundamental implications.
What to watch
The filing notes indirect holdings and post-sale share count, but provides no reason for the sale; traders should avoid extrapolating fundamentals from the sale alone.
Background
The article is an SEC Form 4 insider transaction for Kymera Therapeutics, Inc. (KYMR) by director Booth Bruce, executed 2026-06-23 to 2026-06-25.
Ticker impact
Kymera Therapeutics director Booth Bruce sold $43.99M of KYMR via an open-market sale under a pre-arranged 10b5-1 plan (398,765 shares).
Near-term impact likely limited; any reaction may be sentiment-driven rather than thesis-changing.
The filing is a primary Form 4 disclosure with sale size and pricing range, but it explicitly references a pre-arranged 10b5-1 plan, reducing inference of new negative information.
Market effects
No sector read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, the transaction may reflect routine diversification rather than bearish expectations.
Key entities
- issuerKymera Therapeutics, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderBooth Bruce
Director who sold 398,765 shares of KYMR for ~$43.99M via open-market trades under a 10b5-1 plan.
